The first multiple ascending dose cohort with the subcutaneous version of CAN from healthy subjects supports dosing every 4th week, as suggested by studies of single ascending doses. As a comparison, Humira (adalimumab) is dosed either every week or every second week in HS. 10 single ascending dose cohorts have been completed with the intravenous version showing full receptor occupancy and excellent tolerability at moderate to high doses. One more MAD cohort will be recruited. Two psoriasis MAD cohorts will also be recruited. Cantargia now aims to position CAN10 in HS, a skin disease with currently limited treatment options (based on blockade of TNF alpha and IL-17). The pre-IND feedback supports the plan to submit an application to start a phase II study in HS in H2 2025. Such a study is not yet funded. Considering HS is an attractive indication and phase I data are excellent thus far, we believe partnering CAN10 is a distinct possibility.